As of June 30, Checkpoint’s cash and cash equivalents totaled $7.4M, compared to $4.8M at March 31 and $12.1M at December 31, 2022, an increase of $2.6M for the quarter and a decrease of $4.7M for the first half. Subsequent to the end of the second quarter, Checkpoint raised approximately $10M of gross proceeds in a registered direct offering completed in July.”We continue to work with the U.S. Food and Drug Administration (“FDA”) toward the January 3, 2024 action date for our Biologics License Application (“BLA”) for cosibelimab. Recently, our mid-cycle communication meeting with the FDA was successfully completed, and the FDA noted that no significant review issues or safety concerns have been identified in their review to date,” said James Oliviero, President and Chief Executive Officer of Checkpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- MidCoast Council deploys Check Point Infinity
- Checkpoint to sell 3.2M shares at $3.09 in registered direct offering
- Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
- Checkpoint Therapeutics announces longer-term data for cosibelimab